Ii K, Peng Y, Hirose T, Kannuki S, Matsumoto K
First Department of Pathology, School of Medicine, University of Tokushima 3-18-15, Kuramoto-Cho, Tokushima 770, Japan.
Brain Tumor Pathol. 1997;14(2):87-95. doi: 10.1007/BF02478876.
The immunohistochemical localization of cathepsin D (CD) was demonstrated for the first time in 54 schwannomas (32 intra- and 22 extracranial; 47 benign and 7 malignant) and 5 normal nerve fibers. Granular or vesicular CD-reactive structures were observed in all normal Schwann cells. All tumors contained CD-reactive tumor cells, although the population of CD-reactive tumor cells, the density, intracellular localization, and morphology of CD-reactive structures, and the intensity of CD immunoreactivity varied from case to case, portion to portion, and cell to cell, differing variously from those in normal Schwann cells. The variations were greater in malignant than in benign schwannomas. In mildly degenerate tumor cells, CD immunoreactivity was increased, possibly in response to the increased intracellular degenerate proteins, suggesting that the mechanism of induction of lysosomal proteases preserved in normal cells is not affected by the process of neoplastic transformation. In lesions of severe degeneration or necrosis, CD immunoreactivity was lost in most tumor cells but was strong in macrophages invading the lesions and perivascular regions. CD immunoreactivity was observed at various intensities in tumor cells in the Antoni type A area but not in most tumor cells in the Antoni type B area, suggesting that Antoni type B lesions show degenerative changes. The presence of CD-reactive tumor cells in all tumors examined and strong CD immunoreactivity observed at the invasion front of tumors in some cases of benign or malignant schwannoma suggests the possible role of CD in tumor invasion in some cases.
组织蛋白酶D（CD）的免疫组化定位首次在54例神经鞘瘤（32例颅内和22例颅外；47例良性和7例恶性）及5条正常神经纤维中得以证实。在所有正常雪旺细胞中均观察到颗粒状或囊泡状的CD反应性结构。所有肿瘤均含有CD反应性肿瘤细胞，尽管CD反应性肿瘤细胞的数量、CD反应性结构的密度、细胞内定位和形态以及CD免疫反应强度在不同病例、不同部位和不同细胞之间存在差异，与正常雪旺细胞中的情况有所不同。恶性神经鞘瘤中的差异比良性神经鞘瘤更大。在轻度退变的肿瘤细胞中，CD免疫反应性增强，可能是对细胞内退变蛋白增加的反应，这表明正常细胞中保存的溶酶体蛋白酶诱导机制不受肿瘤转化过程的影响。在严重退变或坏死的病变中，大多数肿瘤细胞中CD免疫反应性丧失，但侵入病变和血管周围区域的巨噬细胞中CD免疫反应性较强。在Antoni A型区域的肿瘤细胞中观察到不同强度的CD免疫反应性，但在Antoni B型区域的大多数肿瘤细胞中未观察到，这表明Antoni B型病变呈现退变改变。在所有检测的肿瘤中均存在CD反应性肿瘤细胞，并且在一些良性或恶性神经鞘瘤病例的肿瘤侵袭前沿观察到强CD免疫反应性，这表明在某些情况下CD可能在肿瘤侵袭中发挥作用。
